Article
Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma.
BMC pharmacology & toxicology - 8 Dec 2025
Ramalingam Prasanna Srinivasan, Hussain Md Sadique, Chellasamy Gayathri, Elangovan Sujatha, Sharma Divya, T Premkumar, Mishra Rudra Awdhesh Kumar, Kodiveri Muthukaliannan Gothandam, Hussain Tajamul, Alrokayan Salman, Balakrishnan Purushothaman, Mekala Janaki Ramaiah, Arumugam Sivakumar
Abstract excerpt
BACKGROUND: Cancer has become a global health threat with increasing incidence & mortality rates, and despite significant advancements in diagnostics and therapeutics, they limited for aggressive cancers like pancreatic ductal adenocarcinoma (PDAC). To note, KRAS-mutated PDAC is very frequent and limited by potent therapeutics due to their aggressiveness. Drug repurposing has become a potent strategy due to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.